Barinthus Biotherapeutics (BRNS) Current Assets (2020 - 2026)
Barinthus Biotherapeutics' (BRNS) quarterly Current Assets came in at $72.7 million in Q1 2026, down 33.87% YoY from $109.9 million in Q1 2025, and down 6.59% on a QoQ basis from $77.8 million in Q4 2025.
Barinthus Biotherapeutics (BRNS) Current Assets (2020 - 2026) Analysis & Trends
Barinthus Biotherapeutics (BRNS) has 7 years of Current Assets data on file, last reported at $72.7 million in Q1 2026.
- Quarterly Current Assets fell 33.87% year-over-year to $72.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $72.7 million (down 33.87% YoY) and the FY2025 annual result came in at $77.8 million, down 38.14% from the prior year.
- Current Assets fell to $72.7 million in Q1 2026, from $77.8 million in the prior quarter.
- In the past five years, Current Assets ranged from a high of $230.8 million in Q1 2022 to a low of $72.7 million in Q1 2026.
- A 5-year average of $152.1 million and a median of $143.1 million in 2024 frame the typical range for Current Assets.
- Annual changes were most pronounced in 2022 — Current Assets surged 41.27% — and 2025, when it sank 38.14%.
- Tracing BRNS's Current Assets over 5 years: stood at $213.0 million in 2022, then declined by 26.35% to $156.9 million in 2023, then slipped by 19.86% to $125.7 million in 2024, then sank by 38.14% to $77.8 million in 2025, then dropped by 6.59% to $72.7 million in 2026.
- The last three Current Assets figures came in at $72.7 million (Q1 2026), $77.8 million (Q4 2025), and $86.8 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.41 Bn | 131.56 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 86.14 Bn | 78.15 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 65.52 Bn | 60.34 Bn | 1.37 Bn | 8.07 Bn |
| 4 | Moderna | 58.21 Bn | 53.07 Bn | 52.00 Mn | 5.82 Bn |
| 5 | BeOne Medicines | 42.15 Bn | 37.05 Bn | 1.53 Bn | 7.22 Bn |
| 6 | Alnylam Pharmaceuticals | 31.62 Bn | 28.31 Bn | 992.69 Mn | 4.62 Bn |
| 7 | BioNTech SE | 27.95 Bn | 9.56 Bn | 668.28 Mn | 18.80 Bn |
| 8 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 1.63 Bn |
| 9 | Royalty Pharma | 27.30 Bn | 26.46 Bn | - | 1.76 Bn |
| 10 | Barinthus Biotherapeutics | 25.29 Mn | 25.29 Mn | - | 63.27 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 63.27 Mn |
| Mar 31, 2026 | 72.66 Mn |
| Dec 31, 2025 | 77.79 Mn |
| Sep 30, 2025 | 86.78 Mn |
| Jun 30, 2025 | 100.41 Mn |
| Mar 31, 2025 | 109.88 Mn |
| Dec 31, 2024 | 125.74 Mn |
| Sep 30, 2024 | 134.65 Mn |
| Jun 30, 2024 | 131.88 Mn |
| Mar 31, 2024 | 143.13 Mn |
| Dec 31, 2023 | 156.91 Mn |
| Sep 30, 2023 | 171.07 Mn |
| Jun 30, 2023 | 184.78 Mn |
| Mar 31, 2023 | 200.67 Mn |
| Dec 31, 2022 | 213.04 Mn |
| Sep 30, 2022 | 218.62 Mn |
| Jun 30, 2022 | 226.29 Mn |
| Mar 31, 2022 | 230.78 Mn |
| Dec 31, 2021 | 226.77 Mn |
| Sep 30, 2021 | 245.98 Mn |